+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Japan Cancer Vaccines Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type; By Indication; By Patient Type; Segments Forecast, 2020-2026

  • ID: 5261922
  • Report
  • June 2020
  • Region: Japan
  • 94 pages
  • Polaris Market Research

FEATURED COMPANIES

  • Aduro BioTech Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb
  • CYTLIMIC
  • Oncolys BioPharma Inc.
  • Takara Bio
The Japan Cancer Vaccines market size is expected to reach USD 1,470.4 Million by 2026, according to the study.

The report “Japan Cancer Vaccines Market Share, Size, Trends, Industry Analysis Report By Type (Prevention Vaccines, Treatment Vaccines, Oncolytic Viruses); Indication (Prostate, Cervical, Others); By Patient Type (Pediatric, Adult); By Regions, Segments & Forecast, 2020-2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.

For several years now, Japan has been experiencing a boom in the incidence of cancer patients. Cancer is one of the major causes of death in Japan. As cancer prevention, the people in Japan mainly follow their traditional low-fat diet which has proven to be effective however, there are certain limitation to this as high salt in the Japanese diet can act as a potential risk for development of stomach cancer. Though Japanese government is promoting various new ways of prevention and treatment of the disease, implementation of cancer vaccines in the healthcare regime is a must and it is necessary for the government to take steps towards usage of these vaccines in Japan.

The primary factor driving the growth of this market in Japan is the growing rate of prevalence of incidence. According to the National Cancer Registry system, in 2016, around 995,132 new patients were diagnosed with cancer of which 566,575 were men and 428,499 were women. Each year, about 10,000 Japanese women are newly diagnosed with the disease while 3,000 die from it. With growing number of patients there is a rising need for a preventive measure that could help stabilize the increasing rate of incidence. Furthermore, growing government initiatives to generate awareness amongst people, and increasing research and development activities are also fueling the growth of this market in Japan.

For instance, in January 2018 the University of Tokyo signed an agreement with the Kanagawa Cancer Center in Yokohama and BrightPath Biotherapeutics for development of a personalized cancer vaccine using a novel method involving the body’s immune response. Furthermore, in February 2018, Japanese Patent Office issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals. Such initiatives and research activities are with an aim of improving the cancer vaccine product line in the Japanese market and thus, fuel the growth of this regional segment.

In 2013, HPV vaccines were added to the national vaccine program in Japan. The same year, several complains were registered proving the side effects associated with cancer vaccines in Japan. This was the major reason for the suspended its recommendation and usage in Japanese industry. Before the suspension around 70% of adolescent girls received the immunization as prevention from cervical cancer. However this number dropped to less than 1% after the health ministry suspended its active recommendation after reports of side effects including muscle pain, sleep disorders, and light and sound sensitivity. Furthermore, companies also restrict from opting to manufacture cancer vaccines as it is a time consuming process with high cost of development and initial setup. These and many such factors are expected to hinder the market growth of cancer vaccines in the Japanese industry during the forecast period.

Japanese government and many local and international companies are taking initiatives to develop the cancer vaccine industry in this region. In order to promote and develop regenerative medicine and cell therapy in Japan, the Act on the Safety of Regenerative Medicine and the Revised Pharmaceutical Affairs Law was enforced in November 2014. Also, Advanced Medical Care is accepted in Japan to evaluate a medical technology at one’s own expense, together with the National Health Insurance, at institutes and hospitals approved by the MHLW. The technological intervention includes regenerative medicine and immunotherapy, the safety and efficacy of which have not been established by previous clinical studies.

Furthermore, many companies are conducting clinical trials to develop and launch innovative vaccines that could help the cancer patients. Companies such as Cytlimic, Aduro Biotech, Oncolys BioPharma, and Otsuka are some of them who have initiated many projects focusing on enhancing their cancer vaccine product line. These initiatives have attracted international funding and thus has created significant growth opportunities for established and emerging players in the global and Japanese cancer vaccines market. The key players in the market include Aduro BioTech, Inc., Astellas Pharma, Inc., Bristol-Myers Squibb, tella, Inc., Oncolys BioPharma Inc., CYTLIMIC, Takeda Pharamceutical, and Takara Bio among others.

The analyst has segmented the Japan Cancer Vaccines market report on the basis of vaccine type, indication and patient type

Japan Cancer Vaccines Types Outlook (Revenue, USD Million, 2016-2026)
  • Prevention Vaccines
  • HPV
  • HBV
  • Treatment Vaccines
  • Antigen vaccines
  • Dendritic cell vaccines
  • DNA vaccines
  • Whole tumor vaccines
  • Anti-idiotype vaccines
  • Oncolytic Viruses
Japan Cancer Vaccines Indication Outlook (Revenue, USD Million, 2016-2026)
  • Prostate
  • Cervical
  • Others
Japan Cancer Vaccines Patient Type Outlook (Revenue, USD Million, 2016-2026)
  • Pediatric
  • Adult
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aduro BioTech Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb
  • CYTLIMIC
  • Oncolys BioPharma Inc.
  • Takara Bio
Chapter 1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

Chapter 2. Executive Summary
2.1. Market Highlights

Chapter 3. Research Methodology
3.1. Overview
3.2. Integrated Ecosystem
3.2.1. Data Mining
3.3. Data Sources
3.3.1. Primary Sources
3.3.2. Secondary Sources

Chapter 4. Market Analysis
4.1. Overview
4.2. Japan Cancer Vaccine Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing Incidences and Prevalence of Cancer
4.2.1.2. Growing Prevalence of Human Papilloma Virus (HPV) Infections
4.2.1.3. Increasing Research and Development Activities
4.2.2. Restraints and Challenges
4.2.2.1. High cost for developing cancer vaccines and time-consuming manufacturing process

Chapter 5. Market Factor Analysis
5.1. Value Chain Analysis/Supply Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of buyers
5.2.2. Bargaining power of suppliers
5.2.3. Threat of new entrants
5.2.4. Threat of substitution
5.2.5. Competitive rivalry
5.3. Regulatory Scenario
5.4. Pipeline Analysis
5.4.1. Cancer Vaccine Pipeline Analysis
5.4.2. Oncolytic viruses Pipeline Analysis
5.5. Stakeholder Mapping
5.5.1. Overview
5.5.2. Stakeholder Identifications
5.5.3. Logical steps and stakeholders for vaccine access improvement
5.5.4. Stakeholder Analysis
5.5.4.1. Stakeholder Details
5.5.4.2. List of Key Participants
5.5.4.2.1. List of Key Participants from Supply Side
5.5.4.2.2. List of Key Participants from Demand side

Chapter 6. Japan Cancer Vaccine Market Assessment by Type
6.1. KEY FINDINGS
6.2. Introduction
6.3. Japan Cancer Vaccine Market, By Type, 2017-2026 (USD Million)
6.4. Prevention Vaccine
6.4.1. Japan Prevention Vaccine Market, by Type, 2017-2026 (USD Million)
6.4.2. HPV
6.4.2.1. Japan HPV Vaccine Market, 2017-2026 (USD Million)
6.4.3. HBV
6.4.3.1. Japan HBV Vaccine Market, 2017-2026 (USD Million)
6.5. Treatment vaccines
6.5.1. Japan Treatment Vaccine Market, by Type, 2017-2026 (USD Million)
6.5.2. Antigen vaccines
6.5.2.1. Japan Antigen Vaccine Market, 2017-2026 (USD Million)
6.5.3. Dendritic cell vaccines
6.5.3.1. Japan Dendritic cell Vaccine Market, 2017-2026 (USD Million)
6.5.4. DNA vaccines
6.5.4.1. Japan DNA Vaccine Market, 2017-2026 (USD Million)
6.5.5. Whole tumor vaccines
6.5.5.1. Japan Whole tumor Vaccine Market, 2017-2026 (USD Million)
6.5.6. Anti-idiotype vaccines
6.5.6.1. Japan Anti-idiotype Vaccine Market, 2017-2026 (USD Million)
6.6. Oncolytic viruses
6.6.1. Japan Oncolytic Viruses Treatment Vaccine Market, 2017-2026 (USD Million)

Chapter 7. Japan Cancer Vaccine Market Assessment by Indication
7.1. KEY FINDINGS
7.2. Introduction
7.3. Japan Cancer Vaccine Market, By Indication, 2017-2026 (USD Million)
7.4. Prostate Cancer
7.4.1. Japan Prstate Cancer Vaccine Market, 2017-2026 (USD Million)
7.5. Cervical Cancer
7.5.1. Japan Cervical Cancer Vaccine Market, 2017-2026 (USD Million)
7.6. Others
7.6.1. Japan Other Cancer Vaccine Market, 2017-2026 (USD Million)

Chapter 8. Japan Cancer Vaccine Market Assessment by Patient Type
8.1. KEY FINDINGS
8.2. Introduction
8.3. Japan Cancer Vaccine Market, By Patient Type, 2017-2026 (USD Million)
8.4. Pediatrics
8.4.1. Japan Cancer Vaccine Market for Pediatrics, 2017-2026 (USD Million)
8.5. Adults
8.5.1. Japan Cancer Vaccine Market for Adult Patients, 2017-2026 (USD Million)

Chapter 9. Competitive Landscape
9.1. Overview
9.2. Competitive Analysis
9.2.1. Key Players - Japan Cancer Vaccine Market
9.3. Strategic Analysis
9.4. Key Developments & Growth Strategies
9.4.1. Research and Development
9.4.2. Partnerships/Collaborations/Agreements/Contracts
9.4.3. Expansion
9.4.4. Others
9.5. Patent Analysis
9.5.1. Key patents in the Industry
9.6. Major Players Financial Matrix & Market ratio
9.6.1. Sales & R&D Expense

Chapter 10. Company Profiles
10.1. Aduro BioTech, Inc.
10.1.1. Business Overview
10.1.2. Financial Snapshot
10.1.3. Products and Services
10.1.4. Recent Developments
10.2. Astellas Pharma, Inc.
10.2.1. Business Overview
10.2.2. Financial Snapshot
10.2.3. Products and Services
10.2.4. Recent Developments
10.3. AstraZeneca PLC
10.3.1. Business Overview
10.3.2. Financial Snapshot
10.3.3. Products and Services
10.3.4. Recent Developments
10.4. Bristol-Myers Squibb
10.4.1. Business Overview
10.4.2. Financial Snapshot
10.4.3. Products and Services
10.4.4. Recent Developments
10.5. GlaxoSmithKline
10.5.1. Business Overview
10.5.2. Financial Snapshot
10.5.3. Products and Services
10.5.4. Recent Developments
10.6. Merck & Co., Inc.
10.6.1. Business Overview
10.6.2. Financial Snapshot
10.6.3. Products and Services
10.6.4. Recent Developments
10.7. tella,Inc.
10.7.1. Business Overview
10.7.2. Financial Snapshot
10.7.3. Products and Services
10.7.4. Recent Developments
10.8. Oncolys BioPharma Inc
10.8.1. Business Overview
10.8.2. Financial Snapshot
10.8.3. Products and Services
10.8.4. Recent Developments
10.9. CYTLIMIC
10.9.1. Business Overview
10.9.2. Financial Snapshot
10.9.3. Products and Services
10.9.4. Recent Developments
10.10. BrightPath Biotherapeutics
10.10.1. Business Overview
10.10.2. Financial Snapshot
10.10.3. Products and Services
10.10.4. Recent Developments
10.11. Daiichi Sankyo Company
10.11.1. Business Overview
10.11.2. Financial Snapshot
10.11.3. Products and Services
10.11.4. Recent Developments
10.12. Otsuka Pharmaceutical Co., Ltd.
10.12.1. Business Overview
10.12.2. Financial Snapshot
10.12.3. Products and Services
10.12.4. Recent Developments
10.13. Takeda Pharmaceutical Company Limited
10.13.1. Business Overview
10.13.2. Financial Snapshot
10.13.3. Products and Services
10.13.4. Recent Developments
10.14. Takara Bio
10.14.1. Business Overview
10.14.2. Financial Snapshot
10.14.3. Products and Services
10.14.4. Recent Developments
10.15. Boston Biomedical (acquired by Dainippon Sumitomo Pharma Co., Ltd: DSP)
10.15.1. Business Overview
10.15.2. Financial Snapshot
10.15.3. Products and Services
10.15.4. Recent Developments
10.16. ImmunoFrontier, Inc.
10.16.1. Business Overview
10.16.2. Financial Snapshot
10.16.3. Products and Services
10.16.4. Recent Developments
10.17. OncoTherapy Science, Inc.
10.17.1. Business Overview
10.17.2. Financial Snapshot
10.17.3. Products and Services
10.17.4. Recent Developments
10.18. Regeneus Ltd
10.18.1. Business Overview
10.18.2. Financial Snapshot
10.18.3. Products and Services
10.18.4. Recent Developments
Note: Product cover images may vary from those shown
  • Aduro BioTech Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb
  • tella Inc.
  • Oncolys BioPharma Inc.
  • CYTLIMIC
  • Takeda Pharmaceutical
  • Takara Bio
Note: Product cover images may vary from those shown
Adroll
adroll